Anders Svenningsson

Publications
Grants
CV
Public outreach and news

Articles

Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2024;95(2):134-141

Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy.

Longinetti E; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould AM; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergård J; Olsson T; Piehl F; Frisell T
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2024;95(2):125-133

Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study.

Silfverberg T; Zjukovskaja C; Ljungman P; Nahimi A; Ahlstrand E; Dreimane A; Einarsdottir S; Fagius J; Iacobaeus E; Hägglund H; Lange N; Lenhoff S; Lycke J; Mellergård J; Piehl F; Svenningsson A; Tolf A; Cherif H; Carlson K; Burman J
Article: ISCIENCE. 2023;26(6):106906

Disease phenotype prediction in multiple sclerosis.

Herman S; Arvidsson McShane S; Zjukovskaja C; Khoonsari PE; Svenningsson A; Burman J; Spjuth O; Kultima K
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023;70:104481

Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort.

Englund S; Kierkegaard M; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergård J; Olsson T; Longinetti E; Frisell T; Piehl F
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1241199

Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay.

Kmezic I; Gustafsson R; Fink K; Svenningsson A; Samuelsson K; Ingre C; Olsson T; Hansson M; Kockum I; Adzemovic MZ; Press R
Article: BRAIN COMMUNICATIONS. 2022;5(1):fcad011

Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis.

Burman J; Zjukovskaja C; Svenningsson A; Freyhult E; Wiberg A; Kultima K
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2022;68:104220

Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis.

Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergård J; Nilsson P; Sundström P; Svenningsson A; Johansson H; Andersen O
Article: BMJ CASE REPORTS. 2022;15(9):e249156

Cerebral microvascular injuries in severe COVID-19 infection: progression of white matter hyperintensities post-infection.

Petersson I; Hansen BM; Svenningsson A; Lundstrom A
Article: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. 2022;9(9):1449-1458

COVID-19 clinical outcomes and DMT of MS patients and population-based controls.

Longinetti E; Bower H; McKay KA; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergård J; Olsson T; Piehl F; Frisell T
Article: LANCET NEUROLOGY. 2022;21(8):693-703

Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial.

Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Nimer FA; Sundström P; Gunnarsson M; Johansson R; Mellergård J; Rosenstein I; Ayad A; Sjöblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
Article: JAMA NEUROLOGY. 2021;78(10):1197-1204

Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis: Data From 2 Different National Strategies.

Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
Article: METABOLITES. 2021;11(2):126

Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing.

Carlsson H; Rollborn N; Herman S; Freyhult E; Svenningsson A; Burman J; Kultima K
Article: JOURNAL OF NEUROLOGY. 2021;268(2):651-657

Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension.

Bergman J; Burman J; Bergenheim T; Svenningsson A
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2020;46:102463

NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS.

Novakova L; Axelsson M; Malmeström C; Zetterberg H; Blennow K; Svenningsson A; Lycke J
Article: MULTIPLE SCLEROSIS JOURNAL. 2020;26(12):1532-1539

Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS.

Granqvist M; Burman J; Gunnarsson M; Lycke J; Nilsson P; Olsson T; Sundström P; Svenningsson A; Vrethem M; Frisell T; Piehl F
Article: FLUIDS AND BARRIERS OF THE CNS. 2020;17(1):49

Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS.

Bergman J; Svenningsson A; Liv P; Bergenheim T; Burman J
Article: ANNALS OF NEUROLOGY. 2020;87(5):688-699

Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients.

Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2020;27(5):871-877

Prevention of post-dural puncture headache: a randomized controlled trial.

Salzer J; Granåsen G; Sundström P; Vågberg M; Svenningsson A
Article: LANCET NEUROLOGY. 2020;19(4):307-316

Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study.

He A; Merkel B; Brown JWL; Zhovits Ryerson L; Kister I; Malpas CB; Sharmin S; Horakova D; Kubala Havrdova E; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T; MSBase study group
Article: METABOLOMICS. 2020;16(2):26

Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry.

Carlsson H; Abujrais S; Herman S; Khoonsari PE; Åkerfeldt T; Svenningsson A; Burman J; Kultima K
Article: JAMA NEUROLOGY. 2020;77(2):184-191

Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies.

Luna G; Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: PAIN. 2019;160(11):2603-2611

Cerebrospinal fluid biomarkers of inflammation in trigeminal neuralgia patients operated with microvascular decompression.

Ericson H; Abu Hamdeh S; Freyhult E; Stiger F; Bäckryd E; Svenningsson A; Gordh T; Kultima K
Article: JOURNAL OF NEUROLOGY. 2019;266(9):2208-2215

Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study.

Söderholm J; Yilmaz A; Svenningsson A; Büsch K; Wejstål R; Brolund A; Kövamees J; Sällberg M; Lagging M; Gisslén M
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2019;26(8):1060-1067

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis.

Boremalm M; Juto A; Axelsson M; Novakova L; Frisell T; Svenningsson A; Lycke J; Piehl F; Salzer J
Article: JOURNAL OF NEUROIMMUNOLOGY. 2019;332:31-36

Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease.

Feresiadou A; Nilsson K; Ingelsson M; Press R; Kmezic I; Nygren I; Svenningsson A; Niemelä V; Gordh T; Cunningham J; Kultima K; Larsson A; Burman J
Article: ACTA NEUROLOGICA SCANDINAVICA. 2019;139(5):462-468

Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial.

de Flon P; Laurell K; Sundström P; Blennow K; Söderström L; Zetterberg H; Gunnarsson M; Svenningsson A
Article: EPIDEMIOLOGY. 2019;30(2):230-233

Validation of the Swedish Multiple Sclerosis Register: Further Improving a Resource for Pharmacoepidemiologic Evaluations.

Alping P; Piehl F; Langer-Gould A; Frisell T; COMBAT-MS Study Group
Article: MULTIPLE SCLEROSIS JOURNAL - EXPERIMENTAL, TRANSLATIONAL AND CLINICAL. 2019;5(1):2055217319826598-205521731982659

Inflammatory activity and vitamin D levels in an MS population treated with rituximab.

Linden J; Granåsen G; Salzer J; Svenningsson A; Sundström P
Article: NEUROLOGY. 2018;91(20):e1893-e1901

Intrathecal treatment trial of rituximab in progressive MS: An open-label phase 1b study.

Bergman J; Burman J; Gilthorpe JD; Zetterberg H; Jiltsova E; Bergenheim T; Svenningsson A
Article: JAMA NEUROLOGY. 2018;75(3):320-327

Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis.

Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
Article: PLOS ONE. 2018;13(2):e0192516

Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls.

de Flon P; Söderström L; Laurell K; Dring A; Sundström P; Gunnarsson M; Svenningsson A
Article: NEUROLOGY. 2017;89(22):2230-2237

Monitoring disease activity in multiple sclerosis using serum neurofilament light protein.

Novakova L; Zetterberg H; Sundström P; Axelsson M; Khademi M; Gunnarsson M; Malmeström C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
Article: MULTIPLE SCLEROSIS JOURNAL. 2017;23(9):1249-1257

Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS.

de Flon P; Laurell K; Söderström L; Gunnarsson M; Svenningsson A
Article: JOURNAL OF NEURORADIOLOGY. 2016;43(6):384-391

Brain parenchymal fraction in an age-stratified healthy population - determined by MRI using manual segmentation and three automated segmentation methods.

Vågberg M; Ambarki K; Lindqvist T; Birgander R; Svenningsson A
Article: IDEGGYOGYASZATI SZEMLE-CLINICAL NEUROSCIENCE. 2016;69(11-12):397-402

How to minimize the risk for headache? A lumbar puncture practice questionnaire study.

Salzer J; Rajda C; Sundström P; Vågberg M; Vécsei L; Svenningsson A
Article: NEUROLOGY. 2016;87(20):2074-2081

Rituximab in multiple sclerosis: A retrospective observational study on safety and efficacy.

Salzer J; Svenningsson R; Alping P; Novakova L; Björck A; Fink K; Islam-Jakobsson P; Malmeström C; Axelsson M; Vågberg M; Sundström P; Lycke J; Piehl F; Svenningsson A
Article: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2016;3(5):e271

Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS.

Bergman J; Dring A; Zetterberg H; Blennow K; Norgren N; Gilthorpe J; Bergenheim T; Svenningsson A
Article: NEUROLOGY. 2016;87(2):141-147

Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab.

de Flon P; Gunnarsson M; Laurell K; Söderström L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundström P; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2016;22(8):1027-1031

Vitamin D and axonal injury in multiple sclerosis.

Sandberg L; Biström M; Salzer J; Vågberg M; Svenningsson A; Sundström P
Article: ANNALS OF NEUROLOGY. 2016;79(6):950-958

Rituximab versus fingolimod after natalizumab in multiple sclerosis patients.

Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Björck A; Axelsson M; Malmeström C; Fink K; Lycke J; Svenningsson A; Piehl F
Article: JOURNAL OF NEUROIMMUNOLOGY. 2016;292:40-44

Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis.

Burman J; Svenningsson A
Article: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2016;3(1):e191

Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination.

Al Nimer F; Elliott C; Bergman J; Khademi M; Dring AM; Aeinehband S; Bergenheim T; Romme Christensen J; Sellebjerg F; Svenningsson A; Linington C; Olsson T; Piehl F
Article: JOURNAL OF NEUROLOGY. 2016;263(2):322-326

Rituximab in paediatric onset multiple sclerosis: a case series.

Salzer J; Lycke J; Wickström R; Naver H; Piehl F; Svenningsson A
Article: ACTA NEUROLOGICA SCANDINAVICA. 2015;132(6):389-394

Increasing prevalence of multiple sclerosis in Västerbotten County of Sweden.

Svenningsson A; Salzer J; Vågberg M; Sundström P; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL - EXPERIMENTAL, TRANSLATIONAL AND CLINICAL. 2015;1:2055217315608203-205521731560820

Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden.

Wickström A; Sundström P; Wickström L; Dahle C; Vrethem M; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2015;21(8):1036-1044

Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF.

Warnke C; Stettner M; Lehmensiek V; Dehmel T; Mausberg AK; von Geldern G; Gold R; Kümpfel T; Hohlfeld R; Mäurer M; Stangel M; Straeten V; Limmroth V; Weber T; Kleinschnitz C; Wattjes MP; Svenningsson A; Olsson T; Hartung H-P; Hermsen D; Tumani H; Adams O; Kieseier BC
Article: NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2015;2(2):e79

Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.

Svenningsson A; Bergman J; Dring A; Vågberg M; Birgander R; Lindqvist T; Gilthorpe J; Bergenheim T
Article: FRONTIERS IN NEUROLOGY. 2015;6:18

Improvement in Fatigue during Natalizumab Treatment is Linked to Improvement in Depression and Day-Time Sleepiness.

Penner I-K; Sivertsdotter EC; Celius EG; Fuchs S; Schreiber K; Berkö S; Svenningsson A; TYNERGY trial investigators
Article: NEUROLOGICAL RESEARCH. 2015;37(1):92-94

Lumbar puncture preferences among Swedish neurologists.

Salzer J; Sundström P; Vågberg M; Svenningsson A
Article: PLOS ONE. 2015;10(7):e0132177

Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light.

Al Nimer F; Thelin E; Nyström H; Dring AM; Svenningsson A; Piehl F; Nelson DW; Bellander B-M
Article: MULTIPLE SCLEROSIS JOURNAL. 2015;21(1):48-56

Age-dependent effects on the treatment response of natalizumab in MS patients.

Matell H; Lycke J; Svenningsson A; Holmén C; Khademi M; Hillert J; Olsson T; Piehl F
Article: PLOS ONE. 2015;10(8):e0135886

Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction.

Vågberg M; Norgren N; Dring A; Lindqvist T; Birgander R; Zetterberg H; Svenningsson A
Article: JOURNAL OF NEUROIMMUNOLOGY. 2014;277(1-2):153-159

The cerebrospinal fluid cytokine signature of multiple sclerosis: a homogenous response that does not conform to the Th1/Th2/Th17 convention.

Burman J; Svensson E; Fransson M; Loskog ASI; Zetterberg H; Raininko R; Svenningsson A; Fagius J; Mangsbo SM
Article: ANNALS OF NEUROLOGY. 2014;76(6):792-801

Cerebrospinal fluid JC virus antibody index for diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy.

Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kümpfel T; Mäurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung H-P; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2014;85(10):1116-1121

Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience.

Burman J; Iacobaeus E; Svenningsson A; Lycke J; Gunnarsson M; Nilsson P; Vrethem M; Fredrikson S; Martin C; Sandstedt A; Uggla B; Lenhoff S; Johansson J-E; Isaksson C; Hägglund H; Carlson K; Fagius J
Article: MULTIPLE SCLEROSIS JOURNAL. 2014;20(8):1095-1101

Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial.

Wickström A; Dahle C; Vrethem M; Svenningsson A
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2014;85(6):618-624

Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP.

Press R; Askmark H; Svenningsson A; Andersen O; Axelson HW; Strömberg U; Wahlin A; Isaksson C; Johansson JEJ; Hägglund H
Article: MULTIPLE SCLEROSIS JOURNAL. 2014;20(1):43-50

Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis.

Axelsson M; Malmeström C; Gunnarsson M; Zetterberg H; Sundström P; Lycke J; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2013;19(5):622-630

Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment.

Wickström A; Nyström J; Svenningsson A
Article: AMERICAN JOURNAL OF NEURORADIOLOGY. 2013;34(3):498-504

Automated determination of brain parenchymal fraction in multiple sclerosis.

Vågberg M; Lindqvist T; Ambarki K; Warntjes JBM; Sundström P; Birgander R; Svenningsson A
Article: PLOS ONE. 2013;8(5):e63172

Intense inflammation and nerve damage in early multiple sclerosis subsides at older age: a reflection by cerebrospinal fluid biomarkers.

Khademi M; Dring AM; Gilthorpe JD; Wuolikainen A; Al Nimer F; Harris RA; Andersson M; Brundin L; Piehl F; Olsson T; Svenningsson A
Article: PLOS ONE. 2013;8(3):e58643

Natalizumab treatment reduces fatigue in multiple sclerosis. Results from the TYNERGY trial; a study in the real life setting.

Svenningsson A; Falk E; Celius EG; Fuchs S; Schreiber K; Berkö S; Sun J; Penner I-K; Tynergy Trial Investigators
Article: NEUROLOGICAL RESEARCH. 2012;34(7):730-733

Humoral immune response to influenza vaccine in natalizumab-treated MS patients.

Vågberg M; Kumlin U; Svenningsson A
Article: BIODRUGS. 2011;25(5):299-306

Effect of treatment with natalizumab on ability to work in people with multiple sclerosis: productivity gain based on direct measurement of work capacity before and after 1 year of treatment.

Olofsson S; Wickström A; Häger Glenngård A; Persson U; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2011;17(6):708-719

A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis.

Holmén C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
Article: ANNALS OF NEUROLOGY. 2011;69(1):83-89

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

Gunnarsson M; Malmeström C; Axelsson M; Sundström P; Dahle C; Vrethem M; Olsson T; Piehl F; Norgren N; Rosengren L; Svenningsson A; Lycke J
Article: CLINICAL NEUROPHARMACOLOGY. 2010;33(5):260-264

Efficacy and safety of the dopaminergic stabilizer Pridopidine (ACR16) in patients with Huntington's disease.

Lundin A; Dietrichs E; Haghighi S; Göller M-L; Heiberg A; Loutfi G; Widner H; Wiktorin K; Wiklund L; Svenningsson A; Sonesson C; Waters N; Waters S; Tedroff J
Article: MULTIPLE SCLEROSIS JOURNAL. 2010;16(3):287-292

Neurofilament light as a prognostic marker in multiple sclerosis.

Salzer J; Svenningsson A; Sundström P
Article: ACTA NEUROLOGICA SCANDINAVICA. 2010;121(1):20-23

Season of birth and multiple sclerosis in Sweden.

Salzer J; Svenningsson A; Sundström P
Article: LANCET NEUROLOGY. 2009;8(6):519-529

NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.

Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr K-M; Søgaard LV; Olsen IC; Sandberg-Wollheim M
Article: NEUROLOGY. 2004;63(9):1586-1590

Neurofilament and glial fibrillary acidic protein in multiple sclerosis.

Norgren N; Sundström P; Svenningsson A; Rosengren L; Stigbrand T; Gunnarsson M
Article: NEUROLOGY. 2004;62(12):2277-2282

An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study.

Sundström P; Juto P; Wadell G; Hallmans G; Svenningsson A; Nyström L; Dillner J; Forsgren L
Article: JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY. 2004;75(5):711-716

Clinical characteristics of multiple sclerosis in Västerbotten County in northern Sweden.

Sundström P; Svenningsson A; Nyström L; Forsgren L
Article: MULTIPLE SCLEROSIS JOURNAL. 2003;9(5):515-520

Sick leave and professional assistance for multiple sclerosis individuals in Västerbotten County, northern Sweden.

Sundström P; Nyström L; Svenningsson A; Forsgren L
Article: ANNALS OF NEUROLOGY. 2002;51(4):467-474

Antibody-mediated suppression of Vbeta5.2/5.3(+) T cells in multiple sclerosis: results from an MRI-monitored phase II clinical trial.

Killestein J; Olsson T; Wallström E; Svenningsson A; Khademi M; Blumhardt LD; Fagius J; Hillert J; Landtblom A-M; Edenius C; Arfors L; Barkhof F; Polman CH
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2002;55(3):264-273

Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis.

Muhallab S; Lundberg C; Gielen AW; Lidman O; Svenningsson A; Piehl F; Olsson T
Article: JOURNAL OF NEUROIMMUNOLOGY. 2001;113(2):202-211

Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis.

Muhallab S; Lidman O; Weissert R; Olsson T; Svenningsson A
Article: JOURNAL OF NEUROSCIENCE. 2000;20(14):5283-5291

Neuroprotection by encephalomyelitis: rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells.

Hammarberg H; Lidman O; Lundberg C; Eltayeb SY; Gielen AW; Muhallab S; Svenningsson A; Lindå H; van Der Meide PH; Cullheim S; Olsson T; Piehl F
Article: NEUROLOGY. 1999;53(8):1880-1882

Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course.

Svenningsson A; Petersson AS; Andersen O; Hansson GK
Article: JOURNAL OF IMMUNOLOGY. 1998;160(2):681-690

Molecular and genetic requirements for preferential recruitment of TCRBV8S2+ T cells in Lewis rat experimental autoimmune encephalomyelitis.

Weissert R; Svenningsson A; Lobell A; de Graaf KL; Andersson R; Olsson T
Article: CYTOMETRY. 1997;29(2):155-164

Identification and analysis of macrophage-derived foam cells from human atherosclerotic lesions by using a "mock" FL3 channel in flow cytometry.

Liu-Wu Y; Svenningsson A; Stemme S; Holm J; Wiklund O
Article: JOURNAL OF NEUROIMMUNOLOGY. 1997;75(1-2):59-68

Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease.

Svenningsson A; Dotevall L; Stemme S; Andersen O
Article: NEUROLOGY. 1996;47(4):895-900

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.

Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Article: MULTIPLE SCLEROSIS JOURNAL. 1996;1(6):348

Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.

Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Article: JOURNAL OF NEUROIMMUNOLOGY. 1995;63(1):39-46

Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid.

Svenningsson A; Andersen O; Edsbagge M; Stemme S
Article: JOURNAL OF LIPID RESEARCH. 1995;36(11):2282-2290

Differential regulation of macrophage scavenger receptor isoforms: mRNA quantification using the polymerase chain reaction.

Dufva M; Svenningsson A; Hansson GK
Article: AUTOIMMUNITY. 1995;21(4):231-239

Reduced frequency of memory CD8+ T lymphocytes in cerebrospinal fluid and blood of patients with multiple sclerosis.

Svenningsson A; Andersen O; Hansson GK; Stemme S
Show more

All other publications

Editorial comment: MULTIPLE SCLEROSIS JOURNAL. 2022;28(8):1177-1178

Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary.

Lycke J; Svenningsson A
Editorial comment: NEUROLOGY. 2021;96(23):1067-1068

Perinatal Depression and Anxiety in Multiple Sclerosis: Treatable Distress.

Leavitt VM; Dobson R; Svennigsson A
Other: NEUROLOGY: CLINICAL PRACTICE. 2019;9(6):519-521

Serum sickness following rituximab therapy in multiple sclerosis.

Holmøy T; Fogdell-Hahn A; Svenningsson A
Letter: PAIN. 2019;160(12):2898-2899

Reply to Sun et al.

Ericson H; Hamdeh SA; Freyhult E; Stiger F; Bäckryd E; Svenningsson A; Gordh T; Kultima K
Review: JAMA NEUROLOGY. 2019;76(9):1035-1048

Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis.

Bridel C; van Wieringen WN; Zetterberg H; Tijms BM; Teunissen CE; and the NFL Group; Alvarez-Cermeño JC; Andreasson U; Axelsson M; Bäckström DC; Bartos A; Bjerke M; Blennow K; Boxer A; Brundin L; Burman J; Christensen T; Fialová L; Forsgren L; Frederiksen JL; Gisslén M; Gray E; Gunnarsson M; Hall S; Hansson O; Herbert MK; Jakobsson J; Jessen-Krut J; Janelidze S; Johannsson G; Jonsson M; Kappos L; Khademi M; Khalil M; Kuhle J; Landén M; Leinonen V; Logroscino G; Lu C-H; Lycke J; Magdalinou NK; Malaspina A; Mattsson N; Meeter LH; Mehta SR; Modvig S; Olsson T; Paterson RW; Pérez-Santiago J; Piehl F; Pijnenburg YAL; Pyykkö OT; Ragnarsson O; Rojas JC; Romme Christensen J; Sandberg L; Scherling CS; Schott JM; Sellebjerg FT; Simone IL; Skillbäck T; Stilund M; Sundström P; Svenningsson A; Tortelli R; Tortorella C; Trentini A; Troiano M; Turner MR; van Swieten JC; Vågberg M; Verbeek MM; Villar LM; Visser PJ; Wallin A; Weiss A; Wikkelsø C; Wild EJ
Other: LAKARTIDNINGEN. 2019;116:FL4F

[Diagnostic challenge in a man with intractable hiccups and vomiting: a case of neuromyelitis optica spectrum disorder (NMOSD)].

Kaloudi D; Svenningsson A; von Heijne A
Editorial comment: NEUROLOGY. 2019;92(7):313-314

Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome.

Zetterberg H; Svenningsson A
Editorial comment: NEUROLOGY. 2017;89(23):2308-2309

Cortico-juxtacortical and periventricular lesions and MS diagnostic criteria.

Svenningsson A; Ciccarelli O
Review: PLOS ONE. 2017;12(1):e0170018

Brain Parenchymal Fraction in Healthy Adults-A Systematic Review of the Literature.

Vågberg M; Granåsen G; Svenningsson A
Review: ACTA NEUROLOGICA SCANDINAVICA. 2017;135(1):17-24

Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society.

Vågberg M; Axelsson M; Birgander R; Burman J; Cananau C; Forslin Y; Granberg T; Gunnarsson M; von Heijne A; Jönsson L; Karrenbauer VD; Larsson E-M; Lindqvist T; Lycke J; Lönn L; Mentesidou E; Müller S; Nilsson P; Piehl F; Svenningsson A; Vrethem M; Wikström J
Letter: ANNALS OF NEUROLOGY. 2016;80(5):791-792

Reply.

Alping P; Frisell T; Svenningsson A; Piehl F
Letter: NEUROLOGY. 2014;83(22):2017-2025

MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study.

Svenningsson A; Sundstrom P; Salzer J; Vagberg M
Letter: LAKARTIDNINGEN. 2014;111(40):1725

[Swedish neurologists--unusually disobedient when it comes to lumbar punctures].

Salzer J; Vågber M; Svenningsson A; Sunddström P
Editorial comment: NEUROLOGY. 2013;80(10):965-967

Fatal neuroinflammation in a case of multiple sclerosis with anti-natalizumab antibodies.

Svenningsson A; Dring AM; Fogdell-Hahn A; Jones I; Engdahl E; Lundkvist M; Brännström T; Gilthorpe JD
Letter: ANNALS OF NEUROLOGY. 2011;69(6):1066-1067

The Neurofilament Light Chain is Not Stable in Vitro Reply

Gunnarsson M; Malmestrom C; Rosengren L; Lycke J; Svenningsson A
Corrigendum: ACTA NEUROLOGICA SCANDINAVICA. 2010;122(1):70-73

Season of birth and multiple sclerosis in Sweden.

Salzer J; Svenningsson A; Sundström P
Review: LAKARTIDNINGEN. 1998;95(49):5631-5635

[Treatment of multiple sclerosis--2. Application of a new immunological basic research is close].

Svenningsson A; Andersson M; Olsson T
Review: LAKARTIDNINGEN. 1998;95(49):5623-5630

[Treatment of multiple sclerosis--1. New drugs may be effective but there still are frequent relapses].

Svenningsson A; Andersson M; Olsson T

Grants

RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS. A randomized trial of long-term dosage of rituximab in multiple sclerosis

Swedish Research Council

1 December 2020 - 31 December 2024
Imatinib for multiple sclerosis relapses

Swedish Research Council

1 January 2018 - 31 December 2020
Randomized phase 3 trial comparing rituximab with dimethyl fumarate in newly diagnosed multiple sclerosis - RIFUND-MS

Swedish Research Council

1 January 2017 - 31 December 2019

Employments

Professor/Senior Physician, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2023-

Degrees and Education

Docent, Karolinska Institutet, 2001

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI